Novo Nordisk cuts Wegovy price in South Africa for a second time - Reuters

Novo Nordisk has reduced the price of Wegovy in South Africa for the second time, signaling the pharmaceutical company's effort to expand access to its obesity drug in emerging markets. Wegovy has faced pricing pressure globally as demand for GLP-1 weight-loss medications surges, prompting manufacturers to balance profitability with affordability concerns in lower-income regions. South Africa represents a significant market opportunity for obesity treatments, though high prices have limited uptake among patients who cannot afford them. By cutting prices repeatedly, Novo Nordisk appears to be addressing affordability barriers that could otherwise restrict the drug's market penetration. The move reflects broader industry trends as competitors like Eli Lilly also navigate pricing strategies across diverse global markets.